Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?

A recent update to the National Cholesterol Education Program's Adult Treatment Panel III guidelines suggests low-density lipoprotein cholesterol (LDL-C) goals of <70 mg/dL in very-high-risk patients and <100 mg/dL in high-risk patients. Currently available 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are not equal in their ability to lower LDL-C, and it is unlikely that the substantial LDL-C reductions that are often needed in high-risk persons can be achieved with starting doses of some of the older statins. Possible alternatives in such cases include the use of high-dose statin therapy, a more efficacious statin, or combination therapy. Recent clinical data have demonstrated a greater likelihood of coronary heart disease event reduction with aggressive statin therapy that lowers LDL-C in a robust fashion (>30%-40%) than with moderate therapy. Until data from ongoing trials of combination therapy are available, however, monotherapy with a potent statin should be initiated to lower LDL-C. Nonetheless, for residual elevation in triglycerides and/or reduced high-density lipoprotein cholesterol, adding a second agent (eg, fenofibrate, niacin) is a reasonable option.     

Travel for HIV care in England: a choice or a necessity?

Objectives

The aims of the study were (1) to measure the distance required to travel, and the distance actually travelled, to HIV services by HIV‐infected adults, and (2) to calculate the proportion of patients who travelled beyond local services and identify socio‐demographic and clinical predictors of use of non‐local services.

Methods

The straight‐line distance between a patient's residence and HIV services was determined for HIV‐infected patients in England in 2007. ‘Local services’ were defined as the closest HIV service to a patient's residence and other services within an additional 5 km radius. Multivariable logistic regression was used to identify socio‐demographic and clinical predictors of accessing non‐local services.

Results

In 2007, nearly 57 000 adults with diagnosed HIV infection accessed HIV services in England; 42% lived in the most deprived areas. Overall, 81% of patients lived within 5 km of a service, and 8.7% used their closest HIV service. The median distance to the closest HIV service was 2.5 km [interquartile range (IQR) 1.5–4.2 km] and the median actual distance travelled was 4.8 km (IQR 2.5–9.7 km). A quarter of patients used a ‘non‐local’ service. Patients living in the least deprived areas were twice as likely to use non‐local services as those living in the most deprived areas [adjusted odds ratio (AOR) 2.16; 95% confidence interval (CI) 1.98–2.37]. Other predictors for accessing non‐local services included living in an urban area (AOR 0.77; 95% CI 0.69–0.85) and being diagnosed more than 12 months (AOR 1.48; 95% CI 1.38–1.59).

Conclusion

In England, 81% of HIV‐infected patients live within 5 km of HIV services and a quarter of HIV‐infected adults travel to non‐local HIV services. Those living in deprived areas are less likely to travel to non‐local services.     

Bezafibrate treatment: a new medical approach for PBC patients?

Background. A new medical approach to primary biliary cirrhosis (PBC) has been desired. We investigated the feasibility of using combination ursodeoxycholic acid (UDCA)-bezafibrate therapy in patients with PBC nonresponsive to UDCA monotherapy. Methods. During a 6-month period, 22 PBC patients with elevated serum alkaline phosphatase (ALP) despite UDCA monotherapy received either UDCA at 600 mg/day (control group) or UDCA at 600 mg/day plus bezafibrate at 400 mg/day (bezafibrate group). Each patient underwent detailed clinical and biochemical evaluation. Results. During treatment, changes in ALP level were greater in the bezafibrate group than in the control group (P < 0.01). During and at the end of treatment, serum ALP levels were significantly lower than those before treatment in patients receiving UDCA plus bezafibrate (P < 0.05). At the end of the 6 months, normalization of serum ALP was observed in 5 of 11 (45.4%) patients given bezafibrate and in 2 of 11 (18.1%) patients not given bezafibrate (P < 0.16). Bile acid proportions during the combination therapy did not change. Pruritus disappeared in 1 of 7 bezafibrate-group patients with this symptom. Conclusions. UDCA at 600 mg/day plus bezafibrate at 400 mg/day may be considered as a new therapeutic option for patients with PBC. Received: August 22, 2002 / Accepted: November 22, 2002 RID="*" ID="*" Reprint requests to: T. Kanda